Related Experiment Video
Updated: Jun 28, 2026
08:49
Cardiac Loading using Passive Left Atrial Pressurization and Passive Afterload for Graft Assessment
Published on: August 2, 2024
Nesiritide in acute decompensated heart failure: current status and future perspectives
Selma F Mohammed1, Josef Korinek, Horng H Chen
1Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
Reviews in Cardiovascular Medicine
|October 28, 2008
Summary
Nesiritide effectively relieves symptoms and reduces filling pressures in patients with acute decompensated heart failure (ADHF). This balanced vasodilator shows no renal toxicity, offering a proven option for severe ADHF cases.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Acute decompensated heart failure (ADHF) presents significant mortality and economic burdens.
- ADHF frequently coexists with comorbidities and advanced age.
- Emerging evidence suggests heart failure involves endogenous B-type natriuretic peptide deficiency or resistance.
Purpose of the Study:
- To evaluate the efficacy and safety of nesiritide in managing ADHF.
- To assess nesiritide's impact on symptom relief and hemodynamic parameters.
Main Methods:
- Clinical trials comparing nesiritide to placebo and nitroglycerin.
- Assessment of symptom improvement, filling pressures, and renal function.
Main Results:
- Nesiritide demonstrated superiority over placebo in rapid symptom relief.
- Nesiritide proved more effective than nitroglycerin in reducing cardiac filling pressures.
- Trials indicated no renal toxicity at recommended nesiritide doses.
Conclusions:
- Nesiritide is an effective therapy for symptomatic normotensive/hypertensive ADHF patients.
- The drug offers balanced vasodilation and beneficial neurohumoral effects.
- Ongoing trials are investigating its impact on mortality.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...